Skip to content

This Website is for UK Healthcare Professionals Only

This Website is for UK Healthcare Professionals Only

Lacrifill | UK LogoLacrifill | UK LogoLacrifill | UK Logo
  • Home
  • Lacrifill
    • Product details
    • Clinical Evidence
    • Suitable patients
    • Administration
    • FAQ
  • Dry Eye
  • Resources
Contact us
Order now
Lacrifill | UK LogoLacrifill | UK LogoLacrifill | UK Logo
  • Home
  • Lacrifill
    • Product details
    • Clinical evidence
    • Suitable patients
    • Administration
    • FAQ
  • Dry Eye
  • Resources
  • Contact
  • Order now

Product details

Product details

Medical device vigilance

To report an adverse event or any other incidents regarding Lacrifill®, please write to:
lacrifill-vigilance@nordicpharma.com

REFERENCES

  1. Packer M, Lindstrom R, Thompson V, Parekh JG, Gupta P, Nijm LM, Donnenfeld E. Effectiveness and safety of a novel crosslinked hyaluronate canalicular gel occlusive device for dry eye. J Cataract Refract Surg. 2024 Oct 1;50(10):1051-1057.
  2. Lacrifill® Instructions for use.
Lacrifill | UK
Nordic Pharma Logo
Lacrifill | UK
Nordic Pharma Logo
  • Privacy Policy
  • Legal Notice
  • Cookies
  • Global Site
  • Privacy Policy
  • Legal Notice
  • Cookies
  • Global Site

[REGULATORY CODE] | [MONTH YEAR]

© 2026 Nordic Pharma, All rights reserved.
Lacrifill® is a registered trademark of Nordic Pharma.

Page load link
Lacrifill | UK LogoLacrifill | UK LogoLacrifill | UK Logo

Interested in Lacrifill®?

If you would like to receive more information about Lacrifill®, be trained or receive samples, please use this form.

Receive more info
Lacrifill | UK LogoLacrifill | UK LogoLacrifill | UK Logo

Welcome

This website is intended for healthcare professionals. By entering this site, you are confirming that you are a healthcare professional.

Are you a healthcare professional?

No
Yes
Go to Top